Clinical Trial Search

Primary: Glycosylated Hemoglobin (HbA1c) Change From Baseline — -1.10; -0.87; -0.39 percentage of HbA1c — p=<0.001

Primary: Steady-state Area Under the Curve (AUC) for Serum Total Immunoglobulin (IgG) — 216873.7; 230830.0 h*mg/dL

Primary: Number of Oocytes Retrieved — 4; 3.4 oocytes

Primary: CBV-fMRI (Cerebral Blood Volume-functional Magnetic Resonance Imaging) — 3.43; 2.55; 2.89; 3.38 percent CBV in a brain region — p=.0001

Primary: Proportion of Responses (Complete Response or Partial Response) — 19.0; 42.9 percentage of participants

Primary: Change in Mean Number of Micturition Episodes Per 24 Hours — -1.9; -2.2 episodes

Primary: Change From Baseline in Hemoglobin A1C (HbA1C) Levels at Week 24 in Participants Receiving Insulin Alone or in Combination With Metformin — -0.67; -0.32 A1C % — p=<0.001

Primary: Change of Alzheimer's Disease Assessment Scale-cognitive Subscale(ADAS-cog)/12 After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule — -2.58; -1.39; -1.45 units on…

Primary: Liver Enzymes(ALT) — 66; 48 IU/L

Primary: Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Success at End of Treatment (LOCF: Last Observation Carried Forward) — 32.1…

Primary: Incidence of Bleeding Events (Major Bleeding, Clinically Relevant Non-major Bleeding and Minor Bleeding ) Identified During the Period From the Entry Into the Treatment…

Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 — 100.0 percentage of participants

Primary: Pain (WOMAC) — 6.1; 6.6; 7.9 units on a scale

Primary: Incidence of All Bleeding — 20.3; 23.8; 29.3 percentage of subjects with bleeds

Primary: Percentage of Patients With TMA Event-free Status — 80 Percentage of Participants